PFE - Pfizer Inc. (NYSE:PFE)

  • Ecco la 60° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Questa settimana abbiamo assistito a nuovi record assoluti in Europa e a Wall Street. Il tutto, dopo una ottava che ha visto il susseguirsi di riunioni di banche centrali. Lunedì la Bank of Japan (BoJ) ha alzato i tassi per la prima volta dal 2007, mettendo fine all’era del costo del denaro negativo e al controllo della curva dei rendimenti. Mercoledì la Federal Reserve (Fed) ha confermato i tassi nel range 5,25%-5,50%, mentre i “dots”, le proiezioni dei funzionari sul costo del denaro, indicano sempre tre tagli nel corso del 2024. Il Fomc ha anche discusso in merito ad un possibile rallentamento del ritmo di riduzione del portafoglio titoli. Ieri la Bank of England (BoE) ha lasciato i tassi di interesse invariati al 5,25%. Per continuare a leggere visita il link

vediamo stasera cosa dice Merck

WHITEHOUSE STATION, N.J., July 21, 2008 - Merck & Co., Inc. today announced financial results for the second quarter of 2008.

Merck reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) of $0.86 for the second quarter of 2008, excluding restructuring charges. GAAP EPS for the second quarter were $0.82. Worldwide sales were $6.1 billion for the quarter, a decrease of 1 percent from the second quarter of 2007. Foreign exchange favorably affected global sales performance by 5 percent for the quarter. Net income for the second quarter of 2008 was $1,768.3 million compared with $1,676.4 million in the second quarter of 2007. For the first six months of 2008, worldwide sales were $11.9 billion and net income was $5,070.8 million.

:cool: OK!

:bye:
 
WHITEHOUSE STATION, N.J., July 21, 2008 - Merck & Co., Inc. today announced financial results for the second quarter of 2008.

Merck reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) of $0.86 for the second quarter of 2008, excluding restructuring charges. GAAP EPS for the second quarter were $0.82. Worldwide sales were $6.1 billion for the quarter, a decrease of 1 percent from the second quarter of 2007. Foreign exchange favorably affected global sales performance by 5 percent for the quarter. Net income for the second quarter of 2008 was $1,768.3 million compared with $1,676.4 million in the second quarter of 2007. For the first six months of 2008, worldwide sales were $11.9 billion and net income was $5,070.8 million.

:cool: OK!

:bye:

il mercato pare aver apprezzato
:D
 

Allegati

  • 1.gif
    1.gif
    16,5 KB · Visite: 130
Viagra helps depressed women get satisfaction, too

Reuters - 22/07/2008 20:39:12



By Julie Steenhuysen
CHICAGO, July 22 (Reuters) - Viagra, a popular anti-impotence pill, may help some women on antidepressants have better sex, U.S. researchers said on Tuesday.

They found women on antidepressants who took Viagra had
fewer sexual side effects than those who took a placebo. Sexual dysfunction can prompt many people to stop taking drugs to treat depression.

While other studies have hinted that Viagra might help these women, the latest research, published in the Journal of the American Medical Association, is one of the first scientifically rigorous studies to show this benefit.

"By treating this bothersome treatment-associated adverse effect ... patients can remain antidepressant-adherent, reduce the current high rates of premature medication discontinuation, and improve depression disease management outcomes," Dr. H. George Nurnberg of the University of New Mexico in Albuquerque and colleagues wrote.

The research was funded by Pfizer Inc <PFE.N, maker of Viagra, which is known generically as sildenafil. Nurnberg has been a paid consultant for the company.

Sexual dysfunction is linked with most commonly used antidepressants, including selective and nonselective serotonin reuptake inhibitors. These drugs represent 90 percent of the 180 million antidepressant prescriptions filled in the United States each year, according to the researchers.

The researchers studied 98 women with an average age of 37 who had symptoms of sexual dysfunction, including delay of orgasm or lack of arousal, and whose depression was in remission after treatment with antidepressants.

Women took a dose of Viagra or the placebo one to two hours before anticipated sexual activity for eight weeks.


While 73 percent of women taking the placebo reported no sexual improvement, only 28 percent of women taking sildenafil failed to benefit.

Related drugs such as Eli Lilly and Co.'s Cialis (LLY.N), known generically as tadalafil, and Levitra or vardenafil, sold by GlaxoSmithKline (GSK.L)(GSK.N), Bayer AG and Schering-Plough (SGP.N), work in a similar way to Viagra.

"These findings are important not only because women experience major depressive disorder at nearly double the rate of men and because they experience greater resulting sexual dysfunction than men, but also because it establishes that (drugs such as sildenafil) are effective in both sexes for this purpose," they wrote.


-------------------------------------------------------------------------------------
Viagra aiuta le donne depresse ottenere soddisfazione, anche

Reuters - 22/07/2008 20:39:12



Di Julie Steenhuysen
CHICAGO, 22 luglio (Reuters) - Viagra, un popolare anti-impotenza pillola, potrebbe aiutare le donne in alcuni antidepressivi hanno più il sesso, i ricercatori degli Stati Uniti ha detto il Martedì.

Essi hanno scoperto le donne a antidepressivi che ha preso il Viagra ha avuto
un minor numero di effetti collaterali sessuali da quelli che ha preso un placebo. Disfunzione sessuale può prompt di molte persone di interrompere l'assunzione di farmaci per curare la depressione.

Mentre altri studi hanno suggerito che il Viagra potrebbe aiutare queste donne, le più recenti della ricerca, pubblicato nel Journal of American Medical Association, è uno dei primi studi scientificamente rigorosi per mostrare questo vantaggio.

"Con questo trattamento fastidio di trattamento associati effetti negativi ... pazienti possono rimanere antidepressivo-aderente, ridurre gli attuali tassi elevati di abbandono prematuro farmaci, la depressione e migliorare la gestione delle patologie, risultati," Dr George H. Nurnberg della University of New Mexico ad Albuquerque e colleghi ha scritto.

La ricerca è stata finanziata da Pfizer Inc, creatore del Viagra, che è conosciuto genericamente come il sildenafil. Nurnberg è stato un consulente pagato per l'azienda.

Disfunzione sessuale è legata a più comunemente usato antidepressivi, tra cui selettiva e nonselective inibitori del reuptake della serotonina. Questi farmaci rappresentano il 90 per cento dei 180 milioni di prescrizioni per antidepressivi riempito negli Stati Uniti ogni anno, secondo i ricercatori.

I ricercatori hanno studiato 98 donne con un'età media di 37 che avevano sintomi di disfunzione sessuale, tra cui ritardo di orgasmo o la mancanza di eccitazione, e di cui la depressione è stata in remissione dopo il trattamento con antidepressivi.

Le donne hanno preso una dose di Viagra o placebo uno a due ore prima della prevista attività sessuale per otto settimane.


Mentre 73 per cento delle donne che assumono il placebo non segnalati miglioramento sessuale, solo il 28 per cento delle donne che assumono sildenafil non ha beneficio.

Relativi farmaci come Eli Lilly and Co 's Cialis noto genericamente come tadalafil e vardenafil o Levitra, venduto da GlaxoSmithKline, Bayer AG e Schering-Ploug, il lavoro in modo simile al Viagra.

"Questi risultati sono importanti non solo perché le donne esperienza disturbo depressivo maggiore a quasi il doppio del tasso di uomini e perché una maggiore esperienza derivante disfunzione sessuale rispetto agli uomini, ma anche perché stabilisce che (come ad esempio la droga sildenafil) sono efficaci in entrambi i sessi per questo obiettivo ", hanno scritto.
 
Earnings Preview: Big challenges for Pfizer
Tuesday July 22, 3:28 pm ET

NEW YORK (AP) -- Pfizer, the world's biggest drugmaker and a Dow component, reports earnings for the second quarter on Wednesday morning. The following is a summary of key developments and analyst opinion related to the period.

OVERVIEW: Pfizer has been hurt by steady declines in U.S. sales, is in a dry spell for major drug approvals and, under its latest restructuring, is aiming to cut costs by $1.5 billion to $2 billion by the end of 2008. Its stock has been in a long slide. In the first quarter, it reported an 18 percent drop in profit, missing Wall Street forecasts, mainly on tougher generic competition for blood-pressure drug Norvasc and allergy drug Zyrtec.

In recent months, concerns about suicidal thoughts have dogged its smoking-cessation pill Chantix and Lyrica, for fibromyalgia pain and seizures. But Pfizer has managed to hold off several patent challenges to protect sales of its cholesterol pill Lipitor, the world's top-selling drug with 2007 revenue of about $12.7 billion.

The company recently has been expanding its oncology business, with a new business unit and some licensing or acquisition deals. The same goes for its animal health business, with the opening of a new center to develop veterinary vaccines in Belgium and the purchase of several vaccines and veterinary medicines from Schering-Plough Corp. in April. It also got U.S. approval for a new antibiotic for cats and dogs, Convenia, a one-time injection for common skin infections.

Pfizer agreed to pay a $975,000 civil penalty to resolve alleged violations of the Clean Air Act at its former manufacturing plant in Groton, Conn.

BY THE NUMBERS: Analysts polled by Thomson Financial expect, on average, earnings per share of 54 cents and revenue of $11.46 billion. In the year-earlier period earnings per share were 18 cents and revenue was $11.08 billion. In the first quarter, earnings per share fell 18 percent to 41 cents from 48 cents in the 2007 period.

ANALYST TAKE: Citigroup analyst John Boris expects U.S. pharmaceutical sales for the quarter to be down 5 percent, but foreign sales up 9 percent, with sales of Lipitor flat and Norvasc down 5 percent. Sales of Lyrica, impotence treatment Viagra and pain reliever Celebrex should be up by double digits, he wrote. But Boris thinks high-margin products are underperforming, so sustained investment is needed to offset cost cuts.

Lehman Brothers analyst Charles Butler writes that management needs to address slowing sales of Chantix and Lipitor, and he expects more cost-cutting moves to be discussed. But he expects to see strong global growth of Lyrica, "one of the few bright spots in the quarter."

WHAT'S AHEAD: Pfizer has said it still expects to meet profit expectations for the full-year: $2.35 and $2.45 per share. But it faces losses of patents for several key drugs from 2010 to 2013, including Lipitor, the world's top-selling medicine.

STOCK PERFORMANCE: Shares fell 16.5 percent to $17.47 during the second quarter. In the first half of 2008, shares fell 23 percent. They sold for $50 nine years ago.
 
il mercato pare aver apprezzato:D

Entrato con 50 pz sui minimi di ieri a circa 31 USD ... :rolleyes:


Merck Announces Fourth Quarter 2008 Dividend

WHITEHOUSE STATION, N.J., July 22, 2008 - The Board of Directors of Merck & Co., Inc., meeting today, declared a quarterly dividend of $0.38 per share on the Company's common stock for the fourth quarter of 2008.

The $0.38 per share dividend is payable on Oct. 1, 2008 to stockholders of record at the close of business on Sept. 5, 2008.

OK!

:bye:
 
Earnings Preview: Big challenges for Pfizer
Tuesday July 22, 3:28 pm ET

NEW YORK (AP) -- Pfizer, the world's biggest drugmaker and a Dow component, reports earnings for the second quarter on Wednesday morning. The following is a summary of key developments and analyst opinion related to the period.

OVERVIEW: Pfizer has been hurt by steady declines in U.S. sales, is in a dry spell for major drug approvals and, under its latest restructuring, is aiming to cut costs by $1.5 billion to $2 billion by the end of 2008. Its stock has been in a long slide. In the first quarter, it reported an 18 percent drop in profit, missing Wall Street forecasts, mainly on tougher generic competition for blood-pressure drug Norvasc and allergy drug Zyrtec.

In recent months, concerns about suicidal thoughts have dogged its smoking-cessation pill Chantix and Lyrica, for fibromyalgia pain and seizures. But Pfizer has managed to hold off several patent challenges to protect sales of its cholesterol pill Lipitor, the world's top-selling drug with 2007 revenue of about $12.7 billion.

The company recently has been expanding its oncology business, with a new business unit and some licensing or acquisition deals. The same goes for its animal health business, with the opening of a new center to develop veterinary vaccines in Belgium and the purchase of several vaccines and veterinary medicines from Schering-Plough Corp. in April. It also got U.S. approval for a new antibiotic for cats and dogs, Convenia, a one-time injection for common skin infections.

Pfizer agreed to pay a $975,000 civil penalty to resolve alleged violations of the Clean Air Act at its former manufacturing plant in Groton, Conn.

BY THE NUMBERS: Analysts polled by Thomson Financial expect, on average, earnings per share of 54 cents and revenue of $11.46 billion. In the year-earlier period earnings per share were 18 cents and revenue was $11.08 billion. In the first quarter, earnings per share fell 18 percent to 41 cents from 48 cents in the 2007 period.

ANALYST TAKE: Citigroup analyst John Boris expects U.S. pharmaceutical sales for the quarter to be down 5 percent, but foreign sales up 9 percent, with sales of Lipitor flat and Norvasc down 5 percent. Sales of Lyrica, impotence treatment Viagra and pain reliever Celebrex should be up by double digits, he wrote. But Boris thinks high-margin products are underperforming, so sustained investment is needed to offset cost cuts.

Lehman Brothers analyst Charles Butler writes that management needs to address slowing sales of Chantix and Lipitor, and he expects more cost-cutting moves to be discussed. But he expects to see strong global growth of Lyrica, "one of the few bright spots in the quarter."

WHAT'S AHEAD: Pfizer has said it still expects to meet profit expectations for the full-year: $2.35 and $2.45 per share. But it faces losses of patents for several key drugs from 2010 to 2013, including Lipitor, the world's top-selling medicine.

STOCK PERFORMANCE: Shares fell 16.5 percent to $17.47 during the second quarter. In the first half of 2008, shares fell 23 percent. They sold for $50 nine years ago.


PROGRESS PROMISE PFIZER
 

Allegati

  • pfizer_logo.gif
    pfizer_logo.gif
    3 KB · Visite: 310
Pfizer: utili più che raddoppiati nel secondo trimestre. Battute le stime anche sul fatturato
Di Alberto Susic


Buone notizie sono appena arrivate dai risultati societari americani e in particolare da Pfizer (NYSE: PFE - notizie) che ha chiuso il secondo trimestre con un utile netto di 2,77 miliardi di dollari, segnando un progresso di oltre il 100% rispetto agli 1,27 miliardi dello stesso periodo dello scorso anno. L'utile per azione è stato di 0,41 dollari, ma al netto di alcune voce straordinarie, il risultato sale a 0,55 dollari, superando di un penny le previsioni degli analisti.

In crescita anche il fatturato che è salito del 9% a 12,1 miliardi di dollari, battendo anche in questo caso le stime della comunità finanziaria che si era preparata ad un incremento meno corposo a 11,5 miliardi di dollari. Il gruppo farmaceutico è riuscito a realizzare questa performance, specie sul fronte degli utili, grazie al taglio dei costi e ai risultati molto positivi raggiunti al di fuori degli Stati Uniti. Pfizer ha inoltre confermato le stime già formulate per l'intero esercizio 2008.
 
Big Pharma: What Safe Haven?

A reputed stronghold for investors, the drugmaking sector faces increasing risks: fewer prescriptions filled, patent expirations, and FDA rejections of new drugs

by Arlene Weintraub senior writer for BusinessWeek's science and technology department

Pharmaceutical stocks have been rallying of late, buoyed by news of richly priced mergers, including Roche's $44 billion bid for Genentech (DNA) on July 21 and the $7 billion offer by generic drugmaker Teva Pharmaceutical Industries (TEVA), a few days earlier, for rival Barr Pharmaceuticals (BRL). But it's not just consolidation that's drawing investors to drug stocks. Even in the face of unprecedented challenges, ranging from patent expirations on billion-dollar products to an increasingly tough regulatory environment, investors keep piling in. On July 15, the market value of health-care stocks in the Standard & Poor's 500-stock index exceeded that of financial-services firms for the first time since 1992. The American Exchange Pharmaceutical Index is up 4.1% since July 1, while the S&P 500 has dropped 1.7%.

But amid this pharmaceutical frenzy, investors got a sobering reminder of just how risky it is to be investing in drugmakers. On July 21, Schering-Plough's (SGP) shares—which had rallied 35% in the prior three months—plunged 12% on news that its embattled cholesterol drug Vytorin performed poorly in a clinical trial. The news also pushed down shares of Merck (MRK), which co-markets Vytorin.

The share declines underscored the risks of flocking to pharmaceutical companies as safe havens in bear markets. Investors often favor drugmakers as an alternative to battered sectors because people generally don't stop taking their prescription drugs when their pocketbooks get squeezed. Most large pharmaceutical companies have healthy cash flows, and they pay generous dividends, even in the worst of economic slumps. What's more, investors can make out fabulously when they place bets on companies that are strong takeover targets: Roche offered a 9% premium over Genentech's previous closing price, while Teva offered to pay 43% more than where Barr's stock had been trading.

Unfounded Reputation for Stability?
The drug industry's safe-haven status is coming into question, as even the most basic assumptions about its stability are proving untrue. In the second quarter, the number of prescriptions fell for the first time since the mid-1990s. Polls show that because of rising health-care costs, patients are more apt to skip doses or cut their pills than they were three years ago. And nearly one-quarter of patients report not filling a prescription because of expenses, says the Henry J. Kaiser Family Foundation.

Add in the long-term threats to the industry, and it starts to look as if cash or perhaps U.S. Treasuries might be a safer investment than drugs. Some of the biggest industry names are facing daunting patent expirations. Pfizer (PFE) will lose its $13 billion-a-year cholesterol blockbuster, Lipitor, to generic competition in 2011. Bristol-Myers Squibb's (BMY) powerhouse blood thinner Plavix, with $5 billion in sales, goes off patent that same year. Merck already lost patent protection for its $3 billion osteoporosis drug, Fosamax, earlier this year.

Drug companies are trying desperately to come up with substitutes for these big products, but even there, Big Pharma is struggling. Part of the problem is that the Food & Drug Administration has become increasingly picky and cautious. The federal regulator has been rejecting more drugs because of safety concerns or a lack of compelling evidence that they represent a true advance over what's already available. In April, Merck suffered two FDA rejections in three days, including one for a cholesterol drug that analysts had predicted would be a blockbuster.

"In terms of generic exposure and the success of the pipeline, it doesn't look great," says Herman Saftlas, a pharmaceutical analyst for Standard & Poor's, which, like BusinessWeek, is owned by The McGraw-Hill Companies (MHP).

Cost-Cutting: Not a Long-Term Fix
History shows that even the dividend isn't sacred in this industry. In 2003, Schering-Plough CEO Fred Hassan slashed the company's dividend to 22¢ a share from 64¢ as part of a turnaround strategy. (The dividend is now 26¢ a share.) Investors were none too happy, and those who have stuck with Hassan have been on a sickening roller-coaster ride. Their shares returned nearly 60% by mid-2007, but then went into a free fall earlier this year, when a study suggested Schering's cholesterol drug Vytorin may be no more effective than cheaper alternatives.

Prior to the recent second round of bad Vytorin news, Schering had been rebounding partly on the success of Hassan's cost-cutting initiatives. Most pharmaceutical companies have spent the last few years slashing sales personnel and implementing efficiency plans to prop up earnings. But there's only so much cutting they can do; slimming efforts may only benefit shareholders in the short term.

Safety in Diversity
Is anything in this sector truly safe? Analysts recommend companies such as Johnson & Johnson (JNJ) and Abbott Laboratories (ABT), which are diversified well beyond prescription drugs. On July 15, J&J beat earnings estimates, thanks in part to a 13% jump in sales of consumer products and over-the-counter drugs. J&J's hit products include Listerine, Tylenol, and most recently, Zyrtec, an allergy drug the company converted from prescription to over-the-counter. Stephen O'Neil, an analyst for Hilliard Lyons, writes in a report that he expects J&J to trade at a 15% premium to the S&P 500 "due to its diverse business, high returns, and strong financial condition." He adds that "no one product or business is likely to dominate [the company's] results," helping it to weather disappointments in its medical devices and drug units. Johnson & Johnson's stock has returned 3% this year. The S&P 500, by contrast, has lost 16%, and the S&P 500 Health Care Index is down 10%.

More merger-and-acquisition activity might fuel rallies in some companies' shares. Picking the right targets could be a challenge, though. Even though Roche had long owned a majority of Genentech's shares, few expected the Swiss giant to swoop in and buy the rest, because European executives there swore they preferred to maintain an arms-length relationship with the South San Francisco (Calif.) biotech. Barr, on the other hand, was a more obvious takeover target; the generic drugmaker's shares had lost 23% of their value in May amid fallout from a surprisingly bad earnings report.

Barr serves as yet another reminder of how one piece of bad news can change virtually everything for a drugmaker in a flash. In a storm, the drug sector may be a beacon to risk-tolerant investors. But a safe haven it's not.
 
Pfizer: utili più che raddoppiati nel secondo trimestre. Battute le stime anche sul fatturato
Di Alberto Susic


Buone notizie sono appena arrivate dai risultati societari americani e in particolare da Pfizer (NYSE: PFE - notizie) che ha chiuso il secondo trimestre con un utile netto di 2,77 miliardi di dollari, segnando un progresso di oltre il 100% rispetto agli 1,27 miliardi dello stesso periodo dello scorso anno. L'utile per azione è stato di 0,41 dollari, ma al netto di alcune voce straordinarie, il risultato sale a 0,55 dollari, superando di un penny le previsioni degli analisti.

In crescita anche il fatturato che è salito del 9% a 12,1 miliardi di dollari, battendo anche in questo caso le stime della comunità finanziaria che si era preparata ad un incremento meno corposo a 11,5 miliardi di dollari. Il gruppo farmaceutico è riuscito a realizzare questa performance, specie sul fronte degli utili, grazie al taglio dei costi e ai risultati molto positivi raggiunti al di fuori degli Stati Uniti. Pfizer ha inoltre confermato le stime già formulate per l'intero esercizio 2008.

PROGRESS PROMISE PFIZER

FROM RESEARCH TOGETHER
 

Allegati

  • pfizer_logo.gif
    pfizer_logo.gif
    3 KB · Visite: 281
Interessantissimo articolo che analizza dal punto di vista dell'impatto valutario i numeri del secondo trimestre sfornati da Pfizer.
Guardate un pò cosa viene fuori.....

Will Pfizer Pfizzle?

By Brian Lawler July 24, 2008

Pfizer (NYSE: PFE) posted respectable second-quarter earnings yesterday, but whether it'll keep up the pace in the quarters to come is anyone's guess.

In the first quarter of the year, Pfizer took a large hit from generic competition, watching revenue and earnings numbers decline year over year. But thanks to a weakening dollar and some aggressive cost cutting, Pfizer turned things around this quarter. The company's revenue grew 9%, while adjusted net income rose 26% year over year.

In fairness, Pfizer took its lumps in years like 2005, when a strong dollar pinched its earnings, without complaining or switching to "constant currency" valuation metrics to distort its financial picture. Still, it's hard not to notice that the biggest constituent of Pfizer's revenue growth this quarter was a seven-percentage-point contribution from changes in the dollar relative to other currencies like the euro. Without this currency benefit, Pfizer would have posted revenue growth of only 2% this quarter year over year. That's much better than Pfizer's 5% year-over-year decline in revenue in the first quarter, but it's still nothing to get excited about.

Even excluding the powerful force of currency effects, Pfizer's lead drug Lipitor did regain some traction. The drugmaker managed to stem hemorrhaging sales of this cholesterol-lowering drug against rivals made by AstraZeneca (NYSE: AZN), Abbott Labs (NYSE: ABT), and Schering-Plough (NYSE: SGP), and generic copies of Merck's (NYSE: MRK) Zocor. Combining this with the continued bad news coming from some rival therapies, and Pfizer's efforts to shore up its patent estate, it was a pretty good quarter for Lipitor.

Nobody expects Pfizer to be a growth stock anymore, nor even post much top-line growth. That made this quarter's top-line growth numbers and even better net income gains such a surprise to observers like me. To be clear, though, this was probably a one-time benefit from cost-cutting and a weak dollar; don't expect such gains to repeat themselves.

All the same, investors on both sides of the Pfizer bull and bear arguments can make good cases for the drugmaker's near-term prospects. Get ready for some volatile times for Pfizer's shares until its future clear ups one way or another.
 
Interessantissimo articolo che analizza dal punto di vista dell'impatto valutario i numeri del secondo trimestre sfornati da Pfizer.
Guardate un pò cosa viene fuori.....

Will Pfizer Pfizzle?

By Brian Lawler July 24, 2008

Pfizer (NYSE: PFE) posted respectable second-quarter earnings yesterday, but whether it'll keep up the pace in the quarters to come is anyone's guess.

In the first quarter of the year, Pfizer took a large hit from generic competition, watching revenue and earnings numbers decline year over year. But thanks to a weakening dollar and some aggressive cost cutting, Pfizer turned things around this quarter. The company's revenue grew 9%, while adjusted net income rose 26% year over year.

In fairness, Pfizer took its lumps in years like 2005, when a strong dollar pinched its earnings, without complaining or switching to "constant currency" valuation metrics to distort its financial picture. Still, it's hard not to notice that the biggest constituent of Pfizer's revenue growth this quarter was a seven-percentage-point contribution from changes in the dollar relative to other currencies like the euro. Without this currency benefit, Pfizer would have posted revenue growth of only 2% this quarter year over year. That's much better than Pfizer's 5% year-over-year decline in revenue in the first quarter, but it's still nothing to get excited about.

Even excluding the powerful force of currency effects, Pfizer's lead drug Lipitor did regain some traction. The drugmaker managed to stem hemorrhaging sales of this cholesterol-lowering drug against rivals made by AstraZeneca (NYSE: AZN), Abbott Labs (NYSE: ABT), and Schering-Plough (NYSE: SGP), and generic copies of Merck's (NYSE: MRK) Zocor. Combining this with the continued bad news coming from some rival therapies, and Pfizer's efforts to shore up its patent estate, it was a pretty good quarter for Lipitor.

Nobody expects Pfizer to be a growth stock anymore, nor even post much top-line growth. That made this quarter's top-line growth numbers and even better net income gains such a surprise to observers like me. To be clear, though, this was probably a one-time benefit from cost-cutting and a weak dollar; don't expect such gains to repeat themselves.

All the same, investors on both sides of the Pfizer bull and bear arguments can make good cases for the drugmaker's near-term prospects. Get ready for some volatile times for Pfizer's shares until its future clear ups one way or another.

La notizia non è certo esaltante... :mmmm:
Cmq Pfizer, in un modo o nell'altro, continua per ora a migliorare i bilanci... Si spera che nel frattempo, mentre vige lo scudo e la leva del cambio favorevole, Pfizer si attivi anche su altri fronti come ad esempio: ottimizzare i guadagni, razionalizzare i costi e soprattutto mettere in commercio nuovi prodotti di successo... :cool:

:bye:


PROGRESS PROMISE PFIZER
 

Allegati

  • pfizer_logo.gif
    pfizer_logo.gif
    3 KB · Visite: 258
Pfizer rimbalza in finale di giornata ! OK!

PROGRESS PROMISE PFIZER
 

Allegati

  • pfizer_logo.gif
    pfizer_logo.gif
    3 KB · Visite: 196
Ho preso profitto a 19.03 e ricomprato tutto a 18,85
;)
 
Ho preso profitto a 19.03 e ricomprato tutto a 18,85
;)

:eek:

19,03 - 18,85 = 0,18 USD :mmmm:

Ehi Ricpast ... ma quante azioni hai movimentato per avere un utile adeguato ??? :confused:

Ric...ordaTi il motto di Soros :

"Sono contento di lasciare il primo 10% di un trend a quelli bravi, di lasciare l'ultimo 10% del trend a quelli bravissimi ... e io che non sono bravo mi accontento dell'80% che sta in mezzo ...!!!"


:bye:


PROGRESS PROMISE PFIZER
 

Allegati

  • pfizer_logo.gif
    pfizer_logo.gif
    3 KB · Visite: 174
Progress Promise Pfizer

OK!
 

Allegati

  • pfizer_logo.gif
    pfizer_logo.gif
    3 KB · Visite: 144
Ha staccato il dvd oggi?
 
Altro accordo che mette la parola fine ad una lunga disputa.
Evidentemente Pfizer, alla luce degli accordi raggiunti negli ultimi 2 mesi, ritiene che la guerra a suon di carte bollate non è molto lungimirante.
Io in linea generale sono d'accordo.
Purtroppo però di qs ultimo accordo non si conoscono i termini....


Pfizer says agreed to settle Lipitor-related suit
Mon Aug 11, 2008

Aug 11 (Reuters) - Pfizer Inc said it has agreed to settle litigation related to its cholestrol drug Lipitor with Canadian generic drug maker Apotex Inc.

"In July 2008, we entered into an agreement with Apotex to settle that litigation, subject to certain conditions," Pfizer said in a quarterly report filed with the U.S. Securities and Exchange Commission,

The company did not provide details of the agreement.

Pfizer has been involved in patent litigation with Apotex to block the launch of generic Lipitor prior to the expiration of a patent that runs through July 2010.

In June, Pfizer settled most of its patent disputes with Ranbaxy Laboratories, allowing the Indian company to launch a generic version of Lipitor from Nov. 30, 2011.

Pfizer could not immediately be reached for comment.
 
Ho preso profitto a 19,99
Un gain di quasi 900 usd che mi serve per la lavatrice appena acquistata
;)

Lo so che voi siete tutti ricchi sfondati e di queste cose si occupa il vs maggiordomo....
:D

Ma io sono un uomo semplice (per quanto bello e dotato... :D ) e molto povero.

Ho pure cambiato un quasi 8000 usd che avevo preso ad un cambio medio di 1,56.
A 1,499 ho ricambiato in euro.

Ora mi metto un pò in attesa.
C'ho solo una montagna di Citi...
:D
 
Anche su PFE si è chiusa la candela di agosto.
Nella seconda parte del mese il titolo ha ritracciato, la forza ribassista è ancora forte e ci potrebbe stare un ritest del supporto attorno a 18,15.

Ritengo ancora valida la mia view che vedrebbe un riavvicinamento del titolo verso la trend line ribassista pluriannuale verso i 22,50-23 usd verso la fine dell'anno.

Attualmente, come detto, sono fuori dal titolo perchè impegnato su altri fronti
:)
 

Allegati

  • 1.jpg
    1.jpg
    101,1 KB · Visite: 252
Indietro